Keyword: Uptravi

jnj

7. Opsumit

With pulmonary arterial hypertension blockbuster Tracleer aging, Actelion in 2013 won FDA approval for Opsumit. The newcomer and fellow PAH product Uptravi have been able to make up for the hole Tracleer’s decline has left.